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AbstrAct
Objectives Describe and compare the risk of 
cardiovascular and non-cardiovascular mortality in 
patients whose antidiabetic therapy is modified to include 
pioglitazone compared with an alternative antidiabetic 
medication at the same stage of disease progression.
Research design and methods This exploratory linked 
database cohort analysis used pooled health and mortality 
data from three European countries: Finland, Sweden and 
the UK. Propensity score together with exact matching 
was used to match 31 133 patients with type 2 diabetes 
first prescribed pioglitazone from 2000 to 2011, to 31 133 
patients never prescribed pioglitazone. Exact matching 
variables were treatment stage, history of diabetes, 
diabetes complications and cardiovascular disease, 
and year of cohort entry. Mean follow-up time was 2.60 
(SD 2.00) and 2.69 (SD 2.31) years in the pioglitazone 
and non-pioglitazone-exposed groups, respectively. 
Crude cause-specific mortality rates were ascertained. 
Association with pioglitazone use was estimated using Cox 
proportional hazards models adjusted a priori for country, 
age, sex, the propensity score quintile and time-dependent 
variables representing use of antidiabetic drugs. Stepwise 
testing identified no additional confounders to include in 
adjusted models.
Results The crude mortality rate was lower in the 
pioglitazone-exposed group than the non-exposed group 
for both cardiovascular and non-cardiovascular mortality. 
Adjusted HRs comparing pioglitazone to alternative 
antidiabetic exposure were 0.58 (95% CI 0.52 to 0.63) and 
0.63 (95% CI 0.58 to 0.68) for cardiovascular and non-
cardiovascular mortality, respectively. A protective effect 
associated with pioglitazone was also found for all specific 
cardiovascular causes.
Conclusions This analysis suggests that pioglitazone is 
associated with a decrease in both cardiovascular and 
non-cardiovascular mortality. Results should be interpreted 
with caution due to the potential for residual confounding 
in this exploratory analysis. Further studies, specifically 
designed to test the association between pioglitazone use 
and patient-focused outcomes, are suggested.
Study registration number European Network of Centres 
for Pharmacoepidemiology and Pharmacovigilance 
(ENCePP; EUPAS3626).
significance of this study
What is already known about this subject?
 ► Evidence from a meta-analysis of seven 
randomized controlled trials indicates that 
pioglitazone exposure did not change the risk 
of death from any cause in patients with type 
2 diabetes, pre-diabetes or insulin resistance. 
These trials were primary designed to study 
cardiovascular and composite outcomes.
 ► Previous secondary analyses of data from the 
original pan-European and other large  
retrospective cohort studies have demonstrated  
a statistically significant reduction in the  
risk of all-cause mortality with pioglitazone  
use.
 ► A range of exploratory studies have demonstrated 
that thiazolidinediones such as pioglitazone may 
have patient benefits beyond diabetes control and 
reduction of cardiovascular risk.
What are the new findings?
 ► This exploratory extension of the pan-European, 
observational, large cohort study suggests that 
exposure to pioglitazone compared with an 
alternative treatment decision at a similar stage 
of disease progression is associated with a 
statistically significant 42% and 37% reduction in 
cardiovascular and non-cardiovascular mortality, 
respectively.
How might these results change the focus of 
research or clinical practice?
 ► The suggestion of potentially broader benefits of 
pioglitazone supports its safe and effective use. 
Lack of agreement between randomized control 
trials and observational studies is likely to be due 
to reduced statistical power in the former and 
unresolved bias in the latter. Findings from this 
study can be used to inform study design for further 
research evaluating the association of pioglitazone 
use with specific long-term diagnostic and mortality 
outcomes.
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InTROduCTIOn
Diabetes mellitus is one of the most common chronic 
diseases worldwide, and its global prevalence continues 
to rise due to the aging population, obesity, urbanization 
and changes associated with lifestyle such as physical inac-
tivity. The increased risk of cardiovascular (CV) disease 
among patients with type 2 diabetes mellitus (T2DM) 
has been studied for many years and is well described in 
the literature. It is estimated that CV disease is respon-
sible for some 70% of all mortality among patients with 
T2DM,1 and newly diagnosed adult diabetic patients have 
5–10 years shorter life expectancy than the general popu-
lation.2 3 
We recently published results from a pan-European 
multidatabase study indicating no evidence of an asso-
ciation between pioglitazone use and bladder cancer 
risk4 when compared with other antidiabetic drugs used 
in patients with T2DM. Further, in the same study, we 
found a statistically significant 33% reduction in all-cause 
mortality associated with pioglitazone use.5 This evidence 
of a reduction in risk of mortality supports other observa-
tional studies,6 7 though findings from a meta-analysis of 
seven trials demonstrate no significant difference in the 
risk of mortality with use of pioglitazone in patients with 
insulin resistance, pre-diabetes and T2DM compared 
with trial comparators.8
A recent review has summarized the findings of a large 
number of preclinical, clinical and observational studies 
that point to an overall beneficial effect of pioglitazone 
on CV disease in patients with T2DM and possible pleio-
tropic benefits.9 We report the findings of post-hoc 
analyses following from our original study findings of a 
reduced all-cause mortality associated with pioglitazone 
use, focusing on cause-specific mortality among patients 
with T2DM using data from Finland (FIN), Sweden 
(SWE) and the UK.
MeTHOdS
Study design and setting
This exploratory linked database cohort analysis used 
three of the six non-overlapping datasets included in 
the bladder cancer and all-cause mortality analyses4 5: 
FIN, SWE and the UK linked GP hospital dataset (UK 
GP-HOSP). Death registration data were not available for 
the remaining datasets. Data from the Clinical Practice 
Research Datalink (CPRD) were used in the UK.
data sources and outcome definition
Drug exposure measures were generated from prescrip-
tion data in the UK and dispensing data in FIN and SWE.
Cause-specific mortality was measured using the under-
lying cause of death field in linked national death regis-
tries in all countries. The following CV-related causes of 
death were classified using International Classification 
of Diseases, Tenth Revision (ICD-10) codes: myocardial 
infarction (MI), stroke, sudden death, congestive heart 
failure (CHF) or cardiogenic shock, renovascular disease, 
peripheral vascular disease, arrhythmia and other CV 
(aortic aneurysm, other) (see online supplementary 
appendix table S1). All other causes of death were clas-
sified as non-CV. All causes of death are summarized by 
ICD-10 code chapter. Additional data from cancer regis-
tries, hospital discharge records, migration records and 
national diabetes registers were used, where available, to 
identify the study cohort and adjust for covariates. The 
study period start and end dates ranged respectively by 
dataset from 1 January 2000 to 1 July 2006 and from 
31 December 2010 to 30 June 2011. The end date for 
the FIN dataset was brought forward by 6 months to 
December 2010 as cause of death data was not available 
after this point.
Participants
The study population comprised of patients with T2DM 
over the age of 40 whose therapy regimen was changed 
to include pioglitazone or any other antidiabetic medi-
cation during the study period. Potential cohort entry 
dates (CEDs) were identified as the date of the first ever 
pioglitazone prescription for pioglitazone-exposed 
patients and the date of switching to or add-on (initia-
tion) of any other antidiabetic medication for the non-pi-
oglitazone-exposed group. CEDs were excluded if there 
were <12 months’ membership in the medication data-
base, any indication of bladder cancer prior to CED or 
if the patients were concurrently exposed to another 
thiazolidinedione.
Matching and covariates
Guidelines recommend a stepwise approach to the 
prescribing of antidiabetic drugs that consider the drug 
substance’s efficacy in controlling blood glucose and its 
safety profile. Clinicians therefore ‘channel’ pioglitazone 
to patients at a specified stage of disease progression and 
with other characteristics that modify their prognosis. As 
stated in the previous manuscript, the following approach 
was taken in an attempt to eliminate channeling bias.10
Propensity scores (PS) were estimated for each CED 
using a weighted logistic regression model with weights 
reciprocal to the number of CEDs per individual. The 
PS model included baseline binary and categorical vari-
ables that were likely to have a direct impact on treat-
ment choice and could be measured in all datasets. 
These included antidiabetic treatment immediately prior 
to CED, whether the treatment change at CED was an 
add-on or switch in therapy, use of thiazolidinediones 
(TZDs) prior to CED, duration of treated diabetes, 
number of different antidiabetic medications used prior 
to CED, history of MI, stroke, heart failure and the 
following diabetic complications: retinopathy or macu-
lopathy, severe lower limb complications, renal compli-
cations, ketoacidosis, and hyperosmolar or ketoacidotic 
coma, duration of prescription database membership 
and calendar year of CED.
Pioglitazone CEDs were 1:1 fixed ratio matched 
and 1:10 variable ratio matched to non-pioglitazone 
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CEDs using the PS distance and the following 
exact matching variables: antidiabetic treatment 
immediately prior to CED, whether the treat-
ment change at CED was an add-on or switch in 
therapy and use of TZDs prior to CED. Non-pioglita-
zone-exposed patients were removed from further 
matching when one of their CEDs was matched to a 
pioglitazone-exposed patient. The number of matched 
non-pioglitazone-exposed patients varied between 
patients and countries in the 1:10 matched cohort, 
resulting in an imbalance in characteristics. The main 
analysis was therefore based on the 1:1 fixed ratio 
matched cohort. Each patient was followed up from 
CED until date of death or censorship due to end of 
membership of the database, end of database coverage, 
start of other TZDs or 30 June 2011. Time-varying (TV) 
covariates were generated to improve the estimation 
of adjusted HRs. The following binary and categorical 
TV covariates were generated for inclusion or testing 
in the regression model: use of each alternative anti-
diabetic treatment class, cumulative duration of expo-
sure to insulin and diagnosis of bladder cancer. Use of 
antidiabetic treatment group other than pioglitazone 
and comorbidity history were categorized as ever versus 
never used and ever versus never occurred up to any 
given time period. Age categories were fixed at baseline.
Statistical analysis
A pooled analysis was performed using the three data-
sets. Standardized differences were used to compare 
pioglitazone-exposed and never-exposed groups, with a 
score <10 indicating good balance. Crude cause-specific 
mortality rates were estimated with 95% CI using Poisson 
regression. Cox proportional hazard models included as 
covariates age, gender, PS quintiles and TV use of antidia-
betic medications. The proportional hazards assumption 
was examined by visually comparing the survival function 
for the pioglitazone-exposed and non-exposed groups. 
Further covariates, exact matching variables, PS variables 
and all variables that were included in the PS were included 
as confounders if their inclusion resulted in a minimum 
of 10% change in the HR of primary exposure (ever vs 
never exposed to pioglitazone) when introduced into the 
base model for the primary analysis for each cause-specific 
mortality outcome. Model selection was not repeated for 
stratified and sensitivity analyses. This differed from the 
all-cause mortality analyses in which exact matching and 
PS variables were automatically included in the adjusted 
model. History of chronic kidney disease/renal impair-
ment, diabetic complications and macrovascular disease 
were added to previous stratified analyses for duration of 
treated diabetes at CED, use of other TZDs prior to CED 
and history of renal complications at CED. Sensitivity 
analyses assessing the results with respect to exposure 
and the inclusion of baseline smoking, baseline body 
mass index (BMI) and TV HbA1c as covariates were 
supplemented with post-hoc analyses adjusting for a log 
transformed continuous age variable, removing patients 
with prior stroke, MI or CHF at CED and country-specific 
analyses.
Further information
Further details about the study methodology are 
published in the BMJ4 and in the European Network of 
Centres for Pharmacoepidemiology and Pharmacovigi-
lance (ENCePP) E-register of studies (study title ‘Pan-Eu-
ropean Multi-Database Bladder Cancer Risk Characteri-
sation Study’).
ReSulTS
The primary pooled matched cohort included 31 133 
patients in both the pioglitazone-exposed and the non-ex-
posed groups. This followed removal of all patients in the 
NL and UK GP datasets, and 1900 and 1 matched pairs 
from the FIN and UK GP-HOSP cohorts respectively due 
to lack of availability of cause-specific mortality data for 
one or both members of the pair. The three-country 
cohorts  are described in table 1. The number of antidi-
abetic treatments prescribed at CED was similar in both 
cohorts. The most commonly prescribed treatment regi-
mens in the never exposed to pioglitazone group were 
insulin alone or in combination (37.5%), metformin and 
sulphonylureas (SU) in combination (22.1%), or combi-
nations of other antidiabetic drugs (30.7%). Pioglitazone 
was prescribed in a variety of treatment regimens: most 
commonly in combination with metformin (36.7%) or 
metformin and SU (25.5%). Imbalance was observed 
in four of the variables used in the PS: MI or stroke at 
CED, CHF at CED, year of CED and duration of medica-
tion database membership prior to CED. The imbalance 
was due to reduced balance in key variables describing 
diabetic complications, history of macrovascular diseases 
and variables describing prior treatment in FIN (online 
supplementary appendix tables 2a-c). 
In country-specific analyses, notable differences were 
observed in a number of covariates. History of TZD at 
cohort entry, a fixed matching variable, was less common 
in FIN (17.3%) than in SWE (38.1%) or the UK (31.4%). 
Among the PS matching variables, diabetic complica-
tions were more common in the UK than in SWE and 
FIN. These differences were particularly pronounced 
for diabetic retinopathy or maculopathy (pioglita-
zone/non-pioglitazone): the UK 20.3%/19.1%; SWE 
8.4%/8.3%; FIN 2.8%/5.5%; and diabetic renal compli-
cations: the UK 16.6%/16.3%; SWE 2.4%/1.9%; FIN 
1.7%/2.7%. Full tables for each country are included in 
the online supplementary appendix tables S2a to S4c.
A total of 6176 deaths (1663 exposed and 4513 non-ex-
posed) occurred during follow-up. This includes 2789 
deaths due to CV-related causes (691 ever and 2098 never 
use of pioglitazone) and 3387 deaths due to non-CV 
causes (972 ever and 2415 never use of pioglitazone).
These events occurred over a mean 2.6 (SD 2.0) years 
of follow-up in the pioglitazone group and 2.7 (SD 2.3) 
in the non-pioglitazone-exposed group. The number of 
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Table 1 Distribution of matching and non-matching covariates at cohort entry
PIO exposed
n=31 133 n (%)
Non-PIO-exposed
n=31 133 n (%)
Standardized 
difference
Dataset
  FIN 15 315 (49.19) 15 315 (49.19) 0.00
  SWE 3712 (11.92) 3712 (11.92) 0.00
  UK GP-HOSP 12 106 (38.88) 12 106 (38.88) 0.00
Exact matching variables
  Type of treatment change at CED
   Add-on 18 774 (60.30) 18 774 (60.30) 0.00
   Switch 12 359 (39.70) 12 359 (39.70) 0.00
  History of TZD at CED
   Never 23 261 (74.71) 23 261 (74.71) 0.00
   Ever 7872 (25.29) 7872 (25.29) 0.00
  Antidiabetic treatment immediately prior to CED*
   Insulin (only or in combination) 1456 (4.68) 1456 (4.68) 0.00
   Metformin and SU 7671 (24.64) 7671 (24.64) 0.00
   Metformin only 10 036 (32.24) 10 036 (32.24) 0.00
   No treatment 3636 (11.68) 3636 (11.68) 0.00
   Other drugs or combination 5405 (17.36) 5405 (17.36) 0.00
   SU only 2929 (9.41) 2929 (9.41) 0.00
Propensity score variables
  Duration of treated diabetes at CED (years)
   <1 3833 (12.31) 3870 (12.43) 0.36
   1 to <2 3923 (12.60) 3571 (11.47) 3.48
   2 to <4 6333 (20.34) 5957 (19.13) 3.03
   4 to <6 6379 (20.49) 7017 (22.54) 4.99
   ≥6 10 665 (34.26) 10 718 (34.43) 0.36
   Range (min, max) (0.00, 34.18) (0.00, 24.79)
   Mean (±SD) 4.77 (3.61) 4.86 (3.62)
   Median (Q1, Q3) 4.24 (1.80, 7.05) 4.43 (1.94, 7.02)
  History of diabetic complications at CED
   Diabetic retinopathy or maculopathy 3189 (10.24) 3460 (11.11) 2.82
   Lower limb severe complications 750 (2.41) 958 (3.08) 4.09
   Diabetic renal complications 2351 (7.55) 2452 (7.88) 1.22
   Ketoacidosis 74 (0.24) 116 (0.37) 2.45
   Hyperosmolar/ketoacidotic coma 661 (2.12) 1097 (3.52) 8.46
  Other comorbidities at CED
   Myocardial infarction or stroke 2687 (8.63) 3853 (12.38) 12.24
   Congestive heart failure 1069 (3.43) 2213 (7.11) 16.50
  Year at CED
   2000–2003 1672 (5.37) 4103 (13.18) 27.17
   2004–2007 11 214 (36.02) 10 573 (33.96) 4.32
   2008–2011 18 247 (58.61) 16 457 (52.86) 11.59
  Duration of medication database membership before 
CED (years)
   1–2 2538 (8.15) 2528 (8.12) 0.12
Continued
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PIO exposed
n=31 133 n (%)
Non-PIO-exposed
n=31 133 n (%)
Standardized 
difference
   3–4 2353 (7.56) 3184 (10.23) 9.39
   5–6 3930 (12.62) 5912 (18.99) 17.52
   7+ 22 312 (71.67) 19 509 (62.66) 19.26
   Range (min, max) (1.00, 22.00) (1.00, 22.00)
   Mean (±SD) 8.86 (4.13) 8.37 (4.13)
   Median (Q1, Q3) 9.00 (6.00, 11.00) 8.00 (5.00, 11.00)
  Different antidiabetic drug classes ever prior to 
CED (n)
   0 1097 (3.52) 1061 (3.41) 0.63
   1 8928 (28.68) 7833 (25.16) 7.94
   2 13 754 (44.18) 12 832 (41.22) 5.99
   3 5833 (18.74) 7204 (23.14) 10.84
   >3 1521 (4.89) 2203 (7.08) 9.25
Non-matching study variables (selected)
  Age at CED (years)
   40–59 12 073 (38.78) 9703 (31.17) 16.01
   60–69 10 355 (33.26) 9506 (30.53) 5.85
   ≥70 8705 (27.96) 11 924 (38.30) 22.10
   Range (min, max) (40.00, 98.00) (40.00, 101.00)
   Mean (±SD) 63.17 (10.68) 65.89 (11.53)
   Median (Q1, Q3) 63.00 (56.00, 71.00) 66.00 (58.00, 75.00)
  Sex
   Male 17 989 (57.78) 17 127 (55.01) 5.59
   Female 13 144 (42.22) 14 006 (44.99) 5.59
  Different antidiabetic drug classes being used at 
CED† (n)
   1 3242 (10.41) 4727 (15.18) 14.31
   2 15 776 (50.67) 16 482 (52.94) 4.54
   3 10 862 (34.89) 9494 (30.49) 9.38
   >3 1253 (4.02) 430 (1.38) 16.36
  Antidiabetic treatment at CED†
   Insulin (only or in combination) 1462 (4.70) 11 662 (37.46) 87.71
   Metformin and SU 7925 (25.46) 6872 (22.07) 7.95
   Metformin only 11 439 (36.74) 2007 (6.45) 79.19
   No treatment 3242 (10.41) 0 (0.00) 48.22
   Other drugs or combination 3830 (12.30) 9571 (30.74) 46.04
   SU only 3235 (10.39) 1021 (3.28) 28.46
  Bladder comorbidities at CED
   Urinary incontinence 1941 (6.23) 2336 (7.50) 5.02
   Urinary tract infection 2458 (7.90) 2818 (9.05) 4.15
   Pyelonephritis 458 (1.47) 604 (1.94) 3.62
   Urolithiasis 809 (2.60) 723 (2.32) 1.78
   Hematuria 1118 (3.59) 1192 (3.83) 1.26
   Urinary retention 369 (1.19) 530 (1.70) 4.34
   Neurogenic bladder 40 (0.13) 50 (0.16) 0.85
Table 1 Continued 
Continued
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PIO exposed
n=31 133 n (%)
Non-PIO-exposed
n=31 133 n (%)
Standardized 
difference
   Catheterization 321 (1.03) 450 (1.45) 3.75
  Other comorbidities at CED
   Other urinary tract cancer (excluding BC) 96 (0.31) 105 (0:34) 0.51
   Other cancer (excluding urinary tract) 3415 (10.97) 4078 (13.10) 6.55
   COPD 2729 (8.77) 2959 (9.50) 2.56
  Use of other medications prior to CED
   Statins 14 933 (47.97) 13 832 (44.43) 7.10
   ARB 9066 (29.12) 7856 (25.23) 8.74
   ACE inhibitors 17 762 (57.05) 18 004 (57.83) 1.57
   BPH 4108 (13.20) 4272 (13.72) 1.54
*Treatments initiated at CED are not included.
†Treatments initiated at CED are included. For the PIO-exposed group, the listed treatments are in addition to PIO.
ARB, angiotensin receptor blockers; BC, bladder cancer; BPH, benign prostatic hypertrophy; CED, cohort entry date; COPD, chronic 
obstructive pulmonary disease;  FIN, Finland; PIO, pioglitazone; SU, sulphonylureas; SWE, Sweden; TZD, thiazolidinedione; UK GP-HOSP, 
UK linked dataset.
Table 1 Continued 
Table 2 Number and percentage of deaths by International 
Classification of Diseases, Tenth Revision (ICD-10) chapter
Cause of death ICD-10 code N (%)
Total 6176 (100.00%)
Circulatory system I00-I99 2834 (45.89%)
Neoplasm C00 - D48 1635 (26.47%)
Respiratory J00-J99 359 (5.81%)
Endocrine, nutritional and 
metabolic
E00-E90 332 (5.38%)
Digestive K00-K93 248 (4.02%)
External cause V01-Y98 228 (3.69%)
Nervous system G00-G99 179 (2.90%)
Mental and behavioral F00-F99 144 (2.33%)
Genitourinary N00-N99 85 (1.38%)
Infectious disease A00-B99 55 (0.89%)
Not classified elsewhere R00-R99 28 (0.45%)
Muscoskeletal and 
connective tissue
M00-M99 24 (0.39%)
Skin and subcutaneous 
tissue
L00-L99 14 (0.23%)
Blood, blood-forming 
organs and immune
D50-D89 7 (0.11%)
Congenital malformations, 
deformations and 
chromosomal 
abnormalities
Q00-Q99 3 (0.05%)
Eye and ear H00-H95 1 (0.02%)
Cardiovascular and metabolic risk
mortality events by ICD-10 chapter is provided in table 2. 
The most common causes of death were circulatory 
system-related deaths (45.9%) and neoplasms (26.5%).
CV versus non-CV mortality
The number of CV and non-CV events and their corre-
sponding crude mortality rates are provided in table 3. 
The rate was lower in the pioglitazone-exposed group 
than the non-exposed group for both CV and non-CV 
mortality. The Kaplan-Meier curves for CV and non-CV 
mortality are consistent with the proportional hazards 
assumption (figure 1A,B).
The adjusted HR for ever exposed compared with 
never exposed to pioglitazone was 0.60 (95% CI 0.57 to 
0.64) for all-cause mortality, 0.58 (95% CI 0.52 to 0.63) 
for CV mortality and 0.63 (95% CI 0.58 to 0.68) for 
non-CV mortality (table 4). No additional variables met 
the confounding inclusion criteria so the base model was 
considered the final model. All three HR estimates were 
statistically significant and indicated a decrease in the risk 
of mortality associated with pioglitazone exposure. The 
protective effect was strongest in the longest duration of 
exposure and highest cumulative dose categories (table 4). 
Discontinuation of pioglitazone use within the last year 
was associated with an increase in the mortality risk.
Significant interactions were observed in stratified 
analyses between pioglitazone exposure and the stratifi-
cation variables (table 5). The reduced risk of all-cause, 
CV and non-CV mortality associated with pioglitazone 
use was stronger in patients with no history of diabetic 
complications, no history of macrovascular diseases and 
no history of chronic kidney disease or renal impairment. 
Duration of treated diabetes at CED, classified as <4 years 
and ≥4 years, was not found to interact with the observed 
associations. The risk reduction for non-CV mortality was 
lower in patients with no history of other TZD use. There 
was a directional but not significant difference in the 
risk reduction for CV mortality in the ever versus never 
received TZD at cohort entry groups.
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Table 3 Number of cardiovascular and non-cardiovascular deaths and their corresponding crude mortality rates
PIO-exposed Non-PIO-exposed
Patients (n) 31 333 31 333
Patient years (mean, SD) 2.6 (2.0) 2.7 (2.3)
Patient years (median, IQR) 2.3 (0.9–3.9) 2.1 (0.8–4.1)
Deaths (n)
Mortality rate per 10 000 
patient-years (95% CI) Deaths (n)
Mortality rate per 10 000 
patient-years (95% CI)
Cardiovascular 691 85.42 (79.28 to 92.03) 2098 250.51 (240.02 to 261.46)
Non-cardiovascular 972 120.15 (112.83 to 127.95) 2415 288.36 (277.09 to 300.1)
All-cause 1663 205.57 (195.92 to 215.69) 4513 538.87 (523.38 to 554.82)
PIO, pioglitazone.
Cardiovascular and metabolic risk
A statistically significant reduction in mortality risk was 
observed in all stratified analyses (table 5) with the excep-
tion of use of TZDs prior to cohort entry for non-CV 
mortality (HR 0.86, 95% CI 0.69, 1.08) and sensitivity 
analyses (online supplementary appendix tables S5a and 
S5b). These included country-specific analyses (table 6). 
For CV-specific mortality, relative risk reduction ranged 
from 7% in the UK GP-HOSP dataset to 65% in SWE. 
For non-CV mortality, the range was from 17% in SWE 
to 51% in FIN. In FIN and UK GP-HOSP, the HR for CV 
mortality is similar to the HR for non-CV mortality. There 
was a considerable difference between the HRs in SWE 
where the protective effect was strongest for CV mortality.
CV mortality subanalyses
The most common CV cause of death in each group 
was MI followed by stroke and heart failure. Together 
these accounted for 88% of CV deaths in both the 
pioglitazone-exposed and non-exposed group. The 
crude mortality rate was lower in the pioglitazone-ex-
posed group than the non-exposed group for each CV 
cause (table 7).
The adjusted HRs for MI, stroke and heart failure were 
0.61 (95% CI 0.55 to 0.69), 0.48 (95% CI 0.38 to 0.62) 
and 0.60 (95% CI 0.42 to 0.86), respectively. A decreased 
risk of mortality was observed for all CV causes with statis-
tical significance demonstrated in all except renovas-
cular disease and peripheral vascular disease (figure 2). 
There were no clear trends with increasing duration of 
pioglitazone use or with increasing cumulative dose 
(online supplementary appendix table S6).
Preplanned stratified analyses were restricted to MI 
and stroke due to low numbers of deaths in other cate-
gories (online supplementary appendix table S7a and 
S7b). The reduced risk of MI-related mortality associated 
with pioglitazone use was stronger in patients with no 
history of macrovascular diseases and for patients with 
no history of diabetic complications. Stratified analyses 
for stroke-related mortality were consistent with the main 
findings. Sensitivity analyses completed for MI, stroke 
and heart failure demonstrated a directional or statis-
tically significant protective effect of pioglitazone in all 
analyses with the exception of MI in the UK (HR 1.05, 
95% CI 0.86 to 1.28) (online supplementary appendix 
tables S8a and S8b).
dISCuSSIOn
In this post-hoc analysis using a large three-country Euro-
pean cohort of patients with T2DM, we found a statis-
tically significant 42% and 37% reduction in risk of CV 
and non-CV mortality, respectively, in patients whose 
antidiabetic therapy was modified to include pioglita-
zone compared with an alternative antidiabetic medica-
tion at a similar stage of disease progression. Compara-
tors included a full range of antidiabetic treatment regi-
mens from metformin alone (6%) to insulin used alone 
or in combination (37%). We also observed a statistically 
significant 39%, 52% and 40% reduction for MI, stroke 
and heart failure cause-specific mortality.
There was no evidence of a consistent trend in 
mortality risk (CV or non-CV) with increasing duration 
of pioglitazone use or with increasing cumulative dose 
of pioglitazone. Discontinuation of exposure to pioglita-
zone within the last year was associated with an increase 
in the mortality risk. This may be due to switch to 
insulin therapy for end-stage patients or undocumented 
pioglitazone treatment during hospitalization that could 
be missing in drug prescription/dispensing registers.
Strengths of the primary study4 include the large 
number of patients included in the study, long follow-up 
period (up to 10 years) and extensive measures to 
reduce or investigate potential biases. These include a 
PS matched cohort design to minimize channeling bias 
related to factors that were hypothesized to influence 
prescribing decisions and be associated with the bladder 
cancer outcome, which was the outcome of interest 
in the main pan-European study. This resulted in the 
pioglitazone-exposed groups in the matched cohort for 
the bladder cancer analysis being balanced with regards 
to the distribution of measured confounders included as 
exact matching variables or in the PS. Marginal exceptions 
included CHF at baseline, early cohort entry (2000–2003) 
and higher duration of medication database membership 
before CED (5–6 and 7+years), where the standardized 
differences marginally exceeded 10. The design included 
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Figure 1 Kaplan-Meier plots of association of exposure to pioglitazone with (A) cardiovascular (CV) mortality and (B) non-CV 
mortality in patients with type 2 diabetes. Ever, exposed to pioglitazone; Never, never exposed to pioglitazone.
Cardiovascular and metabolic risk
further adjustment for matching variables and additional 
baseline and TV confounders in the main regression 
model. We also ran numerous stratifications to identify 
potential effect modification and sensitivity analyses to 
evaluate robustness of study results. These included an 
assessment of the impact of BMI, smoking status and TV 
HbA1c as covariates in countries where these variables 
were available. Remaining limitations were the potential 
for residual confounding due to unmeasured covariates 
such as general health and socioeconomic status11; and 
left truncation of prescribing data, particularly in SWE 
where data collection started in July 2005.4 This left 
truncation may have led to misclassification of incident 
pioglitazone exposure despite the requirement for at 
least 1 year of baseline data prior to index.
These strengths and limitations broadly apply to 
this extended analysis as well. However, the covariates 
and likely mechanisms through which they influence 
the association between pioglitazone exposure and 
outcomes differ for bladder cancer and specific causes 
of mortality. For example, urinary tract or other cancers 
diagnosed either prior to baseline or developing during 
follow-up were not found to be significant confounders 
in the primary analyses for each cause-specific mortality 
outcome and therefore not included in the final models. 
In a study designed specifically to test the association 
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Table 4 Adjusted* HRs for cardiovascular (CV) mortality, non-CV mortality and all-cause mortality
Exposure definitions
CV mortality
HR (95% CI)
Non-CV mortality
HR (95% CI)
All-cause mortality
HR (95% CI)
Pioglitazone exposure
  Never Reference Reference Reference
  Ever 0.58 (0.52 to 0.63) 0.63 (0.58 to 0.68) 0.60 (0.57 to 0.64)
Pioglitazone current exposure
  No Reference Reference Reference
  Yes 0.41 (0.36 to 0.47) 0.30 (0.26 to 0.34) 0.34 (0.31 to 0.38)
Duration of pioglitazone exposure (months)
  Never Reference Reference Reference
  <12 0.56 (0.50 to 0.63) 0.65 (0.58 to 0.71) 0.61 (0.56 to 0.66)
  12–24 0.64 (0.54 to 0.76) 0.61 (0.53 to 0.71) 0.62 (0.56 to 0.70)
  24–48 0.59 (0.49 to 0.71) 0.66 (0.57 to 0.78) 0.63 (0.56 to 0.71)
  >48 0.44 (0.32 to 0.61) 0.45 (0.34 to 0.60) 0.44 (0.36 to 0.55)
Cumulative pioglitazone dose (mg)
  Never Reference Reference Reference
  1–10 500 0.57 (0.51 to 0.64) 0.64 (0.58 to 0.71) 0.61 (0.57 to 0.66)
  10 501–28 000 0.63 (0.54 to 0.73) 0.66 (0.58 to 0.76) 0.64 (0.58 to 0.71)
  28 001–40 000 0.54 (0.40 to 0.72) 0.62 (0.48 to 0.79) 0.58 (0.48 to 0.70)
  >40 000 0.48 (0.36 to 0.66) 0.43 (0.32 to 0.57) 0.45 (0.37 to 0.55)
Time since last exposure (years)
  Never Reference Reference Reference
  Current use 0.38 (0.33 to 0.44) 0.30 (0.27 to 0.35) 0.34 (0.31 to 0.37)
  <1 0.95 (0.81 to 1.10) 1.34 (1.20 to 1.50) 1.17 (1.07 to 1.28)
  1–2 0.61 (0.49 to 0.75) 0.75 (0.62 to 0.89) 0.68 (0.59 to 0.78)
  2–4 0.66 (0.53 to 0.80) 0.74 (0.62 to 0.89) 0.70 (0.61 to 0.80)
  >4 0.77 (0.58 to 1.04) 0.71 (0.54 to 0.93) 0.73 (0.60 to 0.90)
*Adjusted for dataset/country, propensity score quintiles, age at cohort entry dates, sex and ever exposed to metformin, sulphonylureas, 
insulin and other non-insulin diabetic treatments.
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of pioglitazone use with all cancers, patients diagnosed 
with cancer prior to baseline would likely be removed. 
There is also a potential risk that residual confounders 
such as general health and severity of pre-existing condi-
tions have a stronger impact on the association between 
pioglitazone use and cause-specific mortality and 
may partially contribute to the observed association. 
Conversely, there is an increased risk that covariates 
included in the PS model were not associated with the 
mortality outcomes. In order to minimize the effect of 
this, exact matching and individual PS variables were 
not automatically included in the adjusted models in the 
analyses reported here. They were tested as confounders 
using a stepwise methodology but did not meet the 
threshold for inclusion in the final model. This change in 
approach decreased the effect size for all-cause mortality 
from 25% reported in the all-cause mortality manuscript5 
to 14% in the UK-HOSP dataset. In FIN, we observed an 
increase in effect from 46% to 52% which could be due 
to one or both of this change in methodology or the loss 
of matched pairs with CEDs in 2011 and resulting loss of 
covariate balance in multiple PS covariates, notably MI 
or stroke at baseline, CHF at baseline, year of CED and 
duration of medication database membership prior to 
CED. There was no change in SWE.
CV and non-CV mortality risk reductions were observed 
in all countries. In SWE, this reduction was statistically 
significant for CV mortality risk (HR 0.35, 95% CI 0.22 
to 0.56) but smaller and directional for non-CV mortality 
risk (HR 0.83, 95% CI 0.62 to 1.10). Similar differences 
between CV and non-CV mortality risk were not observed 
in FIN and the UK, although both effect sizes were larger 
in FIN and the risk reduction for CV mortality risk was 
not significant in the UK.
Stratified analyses demonstrated statistically signifi-
cant effect modification by history of diabetic compli-
cations, chronic kidney disease and macrovascular 
disease for both CV and non-CV mortality, with a 
weaker risk reduction associated with pioglitazone use 
in patients with a history of these conditions. Diabetic 
complications and renal disease were more common 
in the UK than in SWE and FIN. The reduced risk 
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Table 5 Adjusted HRs for all-cause, cardiovascular (CV) and non-CV mortality in each of the stratified analyses
Strata (category A, category B)
Category A
HR (95% CI)
Category B
HR (95% CI)
P value for 
interaction test
CV mortality
  Duration of treated diabetes (<4, ≥4) 0.59 (0.51 to 0.69) 0.54 (0.48 to 0.60) 0.687
  Use of other thiazolidinediones (never, ever) 0.56 (0.51 to 0.62) 0.72 (0.55 to 0.94) 0.111
  History of diabetic complications (no, yes) 0.52 (0.45 to 0.59) 0.63 (0.54 to 0.72) 0.002
  History of macrovascular disease (no, yes) 0.50 (0.42 to 0.58) 0.63 (0.56 to 0.71) <0.001
  History of chronic kidney disease or renal 
impairment (no, yes)
0.52 (0.47 to 0.58) 0.72 (0.60 to 0.87) 0.008
Non-CV mortality
  Duration of treated diabetes (<4, ≥4) 0.64 (0.57 to 0.72) 0.63 (0.56 to 0.70) 0.339
  Use of other thiazolidinediones (never, ever) 0.60 (0.55 to 0.65) 0.86 (0.69 to 1.08) 0.004
  History of diabetic complications (no, yes) 0.57 (0.51 to 0.63) 0.69 (0.61 to 0.78) 0.004
  History of macrovascular disease (no, yes) 0.58 (0.52 to 0.64) 0.70 (0.62 to 0.80) <0.001
  History of chronic kidney disease or renal 
impairment (no, yes)
0.58 (0.52 to 0.63) 0.75 (0.64 to 0.89) 0.013
All-cause mortality
  Duration of treated diabetes (<4, ≥4) 0.62 (0.56 to 0.68) 0.58 (0.53 to 0.63) 0.836
  Use of other thiazolidinediones (never, ever) 0.58 (0.54 to 0.62) 0.80 (0.67 to 0.95) 0.001
  History of diabetic complications (no, yes) 0.54 (0.5 to 0.59) 0.66 (0.60 to 0.72) <0.001
  History of macrovascular disease (no, yes) 0.55 (0.5 to 0.6) 0.66 (0.61 to 0.72) <0.001
  History of chronic kidney disease or renal 
impairment (no, yes)
0.55 (0.51 to 0.59) 0.74 (0.65 to 0.84) <0.001
Table 6 Adjusted HRs for all-cause, cardiovascular (CV) and non-CV mortality in each dataset
Sensitivity analysis
CV mortality
HR (95% CI)
Non-CV mortality
HR (95% CI)
All-cause
HR (95% CI)
FIN 0.46 (0.41 to 0.53) 0.49 (0.44 to 0.55) 0.48 (0.44 to 0.52)
SWE 0.35 (0.22 to 0.56) 0.83 (0.62 to 1.10) 0.63 (0.49 to 0.80)
UK GP-HOSP 0.93 (0.79 to 1.09) 0.82 (0.72 to 0.94) 0.86 (0.78 to 0.95)
Pooled data 0.58 (0.52 to 0.63) 0.63 (0.58 to 0.68) 0.60 (0.57 to 0.64)
FIN, Finland; SWE, Sweden; UK GP-HOSP, UK linked dataset.
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of both CV and non-CV mortality was weaker in the 
UK sensitivity analysis. Given the use of primary care 
data in the UK in addition to the secondary care data 
sources used in all three countries, these differences 
may in part reflect differences in data recording. This 
may lead to variation in PS modeling and matching 
with the UK model better able to minimize channeling 
bias. Conversely misclassification of exposure may be 
higher in the UK where analyses rely on prescribing 
data than in FIN and SWE where dispensing data were 
used. Assuming that misclassification was non-differ-
ential, this would attenuate the observed protective 
effect in the UK. Country differences may also reflect 
true differences in diabetic complications and renal 
disease attenuating the beneficial effect of pioglita-
zone or differences in other characteristics and care 
received by patients prescribed pioglitazone in the 
three countries. Cause of death registers in all three 
countries use WHO ICD-10 to code underlying cause 
of death and follow internationally agreed rules.12–15 
Differential coding of cause of death between coun-
tries and between pioglitazone-exposed and unex-
posed groups is therefore unlikely.
Stratified analyses for history of TZD at cohort 
entry showed a stronger protective effect with 
pioglitazone use in patients with no history of TZD 
use for non-CV mortality where the effect was statis-
tically significant and CV mortality where the effect 
was directional. For CV mortality, this risk difference 
may be explained by the propensity of rosiglitazone 
to increase CV risk which led to its withdrawal from 
the UK market in 2010.11 Interestingly, history of 
TZD use at cohort entry was less common in FIN 
than in SWE and the UK and the risk reduction for 
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Table 7 Number of cardiovascular cause-specific deaths and their corresponding crude mortality rates per 10 000 person-
years
Ever exposed to pioglitazone
n=31 133
Never exposed to pioglitazone
n=31 133
N
Mortality rate per 10 000 
patient-years (95% CI) N
Mortality rate per 10 000 
patient-years (95% CI)
Myocardial infarction 467 57.73 (52.72 to 63.21) 1380 164.78 (156.31 to 173.71)
Stroke 92 11.37 (9.27 to 13.95) 340 40.6 (36.5 to 45.15)
Heart failure 47 5.81 (4.37 to 7.73) 132 15.76 (13.29 to 18.69)
Peripheral vascular disease 15 1.85 (1.12 to 3.08) 33 3.94 (2.8 to 5.54)
Arrhythmia 9 1.11 (0.58 to 2.14) 42 5.01 (3.71 to 6.79)
Renovascular disease 1 0.12 (0.02 to 0.88) 12 1.43 (0.81 to 2.52)
Sudden death* 0 2
Other cardiovascular diseases of interest 60 7.42 (5.76 to 9.55) 157 18.75 (16.03 to 21.92)
*Mortality not calculated due to lack of statistical convergence of the model.
Figure 2 Adjusted HRs with 95% CI for the association between pioglitazone use and cause-specific mortality. CVD, 
cardiovascular disease.
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non-CV mortality was greater in the FIN sensitivity 
analysis.
Liao et al recently published a meta-analysis of nine 
randomized controlled trials evaluating the effect 
of pioglitazone on CV and safety outcomes. This 
meta-analysis demonstrated a significantly reduced 
risk of major CV events (composite of non-fatal 
MI, non-fatal stroke and CV death) in patients with 
diabetes (relative risk (RR) 0.83, 95% CI 0.72 to 
0.97) and pre-diabetes or insulin resistance (RR 
0.77, 95% CI 0.64 to 0.93).8 This is in line with our 
finding of a protective effect for pioglitazone on CV 
mortality compared with other antidiabetic treatments 
prescribed at similar stage of disease progression. The 
meta-analysis also demonstrated an increased risk of 
CHF with pioglitazone (RR 1.32; CI 1.14 to 1.54). This 
contradicts our findings of a protective effect for CHF 
mortality (HR 0.60, 95% CI 0.42 to 0.86), perhaps 
reflecting adherence to warnings about the safety 
of pioglitazone prescribing in patients with heart 
failure when used in the real-world setting, following 
publication of the PROspective pioglitAzone Clinical 
Trial In macroVascular Events (PROactive) random-
ized control trial.9
There is little evidence from randomized controlled 
trials and observational studies examining the associ-
ation of pioglitazone with non-CV patient outcomes 
and mortality with which to compare findings from this 
study. However, no statistically significant difference 
was observed in the rate of all-cause mortality in Liao et 
al’s meta-analysis (seven trials; RR 0.93, 95% CI 0.80 to 
1.09).8 The vast majority (90%) of the 11 319 subjects 
in the meta-analysis were enrolled in two large trials: 
the PROactive16 17 trial in patients with type 2 diabetes 
at high risk of CV disease and the Insulin Resistance 
Intervention after Stroke (IRIS) trial in pre-diabetic 
patients with a history of ischemic stroke or transient 
ischemic attack. The result from the meta-analysis 
contradicts the findings from the current analysis and 
other large observational studies with long follow-up 
periods that have demonstrated significant reductions 
in all-cause mortality risk with pioglitazone use over 
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longer follow-up periods.5–7 This lack of agreement is 
likely to be due to a combination of reduced statistical 
power in randomized control trials designed primarily 
to study CV and composite outcomes, residual bias 
in observational studies primarily designed to study 
cancer outcomes and differences between the charac-
teristics of patients enrolled or included in the studies.
Cancer was assessed as a safety outcome in Liao et al’s 
meta-analysis in which a directional protective effect 
was observed (four trials; RR 0.91, CI 0.77 to 1.08).8 
Suggested mechanisms for CV and non-CV benefits of 
pioglitazone, based on preclinical and clinical studies, 
include improvements in insulin resistance, decreased 
hyperglycemia, fat redistribution, renoprotection 
and improved liver function.9 A protective effect of 
pioglitazone for non-CV mortality is therefore plau-
sible. Further research is required in this area before 
conclusions can be drawn.
Conclusions
This extended analysis following a large, observational multi-
database European cohort study found that prescribing 
pioglitazone compared with an alternative treatment deci-
sion at a similar stage of disease progression was associated 
with a reduction in both CV and non-CV mortality. Further 
observational and prospective studies that are specifi-
cally designed to test the association between pioglitazone 
use and patient-focused outcomes such as cause-specific 
mortality are suggested. Observational study designs should 
consider the nature of prescribing over time in the countries 
of interest and effect modification by prior TZD prescribing, 
history of diabetic complications and history of macrovas-
cular disease.
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